Content about Pfizer

June 13, 2011

Merck will collaborate with a Korean manufacturer to develop a biosimilar version of a drug used for autoimmune diseases.

WHITEHOUSE STATION, N.J. — Merck will collaborate with a Korean manufacturer to develop a biosimilar version of a drug used for autoimmune diseases.

Merck, which operates outside the United States and Canada as MSD to avoid confusion with Germany-based Merck KGaA, announced Monday a collaboration with Seoul, South Korea-based Hanwha Chemical to develop and commercialize HD203, a biosimilar version of Enbrel (etanercept), made by Amgen and Pfizer. The drug is used to treat such disorders as rheumatoid arthritis and psoriasis.

June 7, 2011

Dr. Reddy's Labs has received regulatory approval from the Food and Drug Administration for generic versions of treatments for Alzheimer's disease, depression and breast cancer.

HYDERABAD, India — Dr. Reddy's Labs has received regulatory approval from the Food and Drug Administration for generic versions of treatments for Alzheimer's disease, depression and breast cancer.

The drug maker said that the FDA approved donepezil hydrochloride tablets, a generic version of Pfizer and Eisai's Arciept, in the 5-mg and 10-mg strengths for the treatment of Alzheimer's disease. Both strengths will be available in 30-, 90- and 500-count bottles.

June 7, 2011

Global Wellness on Tuesday initiated a voluntary nationwide recall of its Via Extreme ultimate sexual enhancer dietary supplement for men.

HOLLYWOOD, Fla. — Global Wellness on Tuesday initiated a voluntary nationwide recall of its Via Extreme ultimate sexual enhancer dietary supplement for men.

The product — a bottle containing six blue-colored capsules per package — was distributed throughout the United States, Puerto Rico and Canada to Internet and retail consumers, the company reported.

Global Wellness is recalling only lots 809013 and 806030; the recall does not affect sales and distribution of Slim Extreme Gold and Gelslim, the company stated.

June 7, 2011

The Food and Drug Administration has approved a generic contraceptive made by Watson Pharmaceuticals, the company said Tuesday.

PARSIPPANY, N.J. — The Food and Drug Administration has approved a generic contraceptive made by Watson Pharmaceuticals, the company said Tuesday.

Watson announced the approval of levonorgestrel and ethinyl estradiol tablets in the 0.09-mg/0.02-mg strength.

The drug is a generic version of Pfizer’s Lybrel, which had sales of slightly less than $12 million during the 12-month period that ended in April, according to IMS Health.

June 3, 2011

Pfizer has filed suit against generic drug maker Impax Labs in connection with the latter’s attempt to market a generic drug for bladder problems.

HAYWARD, Calif. — Pfizer has filed suit against generic drug maker Impax Labs in connection with the latter’s attempt to market a generic drug for bladder problems.

Impax said Friday that Pfizer filed a patent infringement suit in the U.S. District Court of the District of New Jersey in connection with Impax’s attempt to market a generic version of Detrol (tolterodine tartrate) immediate-release tablets in the 1-mg and 2-mg strengths. The drug is used to treat overactive bladder and urinary incontinence.

June 3, 2011

Generic drug maker Watson Labs is hoping to market a generic version of a Pfizer drug for erectile dysfunction.

PARSIPPANY, N.J. — Generic drug maker Watson Labs is hoping to market a generic version of a Pfizer drug for erectile dysfunction.

Watson announced Thursday that it had filed a regulatory approval application with the Food and Drug Administration to market a generic version of Viagra (sildenafil citrate) tablets in 25-mg, 50-mg and 100-mg strengths.

June 2, 2011

The Food and Drug Administration has approved a generic drug for depression and anxiety made by Mylan, the drug maker said Thursday.

PITTSBURGH — The Food and Drug Administration has approved a generic drug for depression and anxiety made by Mylan, the drug maker said Thursday.

Mylan announced the approval of venlafaxine hydrochloride extended-release capsules in the 37.5-mg, 75-mg and 150-mg strengths.

The drug, used to treat major depressive disorder and social anxiety disorder, is a generic version of Effexor XR, made by Wyeth. Mylan is launching the drug under a licensing agreement it made with Wyeth before its purchase by Pfizer.

June 2, 2011

The Food and Drug Administration has approved a generic drug for Alzheimer’s disease made by Teva Pharmaceutical Industries.

JERUSALEM — The Food and Drug Administration has approved a generic drug for Alzheimer’s disease made by Teva Pharmaceutical Industries.

The FDA approved Teva’s donepezil hydrochloride tablets in the 5-mg and 10-mg strengths.

The drug is a generic version of Aricept, made by Pfizer and Eisai. Branded and generic versions of the drug had sales of about $2.3 billion during the 12-month period ended in March, according to IMS Health.

June 1, 2011

The Food and Drug Administration has approved a generic treatment for Alzheimer’s disease made by Actavis, the drug maker said Tuesday.

MORRISTOWN, N.J. — The Food and Drug Administration has approved a generic treatment for Alzheimer’s disease made by Actavis, the drug maker said Tuesday.

The FDA approved the company’s donepezil hydrochloride tablets in the 5-mg and 10-mg strengths, a generic version of Eisai and Pfizer’s Aricept. Donepezil hydrochloride tablets in the two strengths had sales of about $2.3 billion during the 12-month period ended in March, according to IMS Health.

June 1, 2011

Sandoz has launched generic versions of treatments for Alzheimer’s disease, the generic pharmaceuticals division of Swiss drug maker Novartis said Wednesday.

PRINCETON, N.J. — Sandoz has launched generic versions of treatments for Alzheimer’s disease, the generic pharmaceuticals division of Swiss drug maker Novartis said Wednesday.

Sandoz announced the launch of donepezil hydrochloride film-coated tablets and donepezil hydrochloride orally disintegrating tablets, which are generic versions of Eisai and Pfizer’s Aricept and Aricept ODT, respectively.

Donepezil hydrochloride film-coated and orally disintegrating tablets had sales of $2.3 billion in the 12-month period ended in March, according to IMS Health.

May 24, 2011

The Food and Drug Administration has approved a generic over-the-counter treatment for allergies made by Taro Pharmaceutical Industries.

HAWTHORNE, N.Y. — The Food and Drug Administration has approved a generic over-the-counter treatment for allergies made by Taro Pharmaceutical Industries.

Taro announced Monday the approval of cetirizine hydrochloride oral solution.

The drug, a generic version of Johnson & Johnson’s children’s Zyrtec, is used to relieve symptoms of indoor and outdoor allergies and is available in a sugar-free bubblegum flavor.

May 23, 2011

The summer 2011 Allergy Relief Ingredient Guide breaks down the indication, active ingredients, purpose and dosage of such OTC allergy-symptom relievers as Claritin, Allegra, Zyrtec, Benadryl, Hyland's, Ocean, Similasan, Visine A.C. and Zaditor.

The summer 2011 Allergy Relief Ingredient Guide breaks down the indication, active ingredients, purpose and dosage of such OTC allergy-symptom relievers as Claritin, Allegra, Zyrtec, Benadryl, Hyland's, Ocean, Similasan, Visine A.C. and Zaditor.

Click here for the complete guide.

May 23, 2011

The FDA has approved a new treatment for Type 2 diabetes, the agency said. The FDA announced the approval of Tradjenta (linagliptin) made by Indianapolis-based Eli Lilly and German drug maker Boehringer Ingelheim.


SUPPLIER NEWS — The FDA has approved a new treatment for Type 2 diabetes, the agency said. The FDA announced the approval of Tradjenta (linagliptin) made by Indianapolis-based Eli Lilly and German drug maker Boehringer Ingelheim.


May 23, 2011

The Food and Drug Administration has approved a Pfizer drug for treating pancreatic tumors.

NEW YORK — The Food and Drug Administration has approved a Pfizer drug for treating pancreatic tumors.

Pfizer announced Friday the approval of Sutent (sunitinib malate) for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with locally advanced disease that can’t be removed through surgery. Pancreatic NET is a rare cancer reported in 2 million to 4 million people worldwide every year.

May 10, 2011

The Food and Drug Administration expects to approve an increasing number of drugs, according to published reports.

NEW YORK — The Food and Drug Administration expects to approve an increasing number of drugs, according to published reports.

Reuters quoted FDA Center for Drug Evaluation and Research director Janet Woodcock as saying the number of drugs approved gradually could increase, already having reached a “nadir.” The report noted that 12 drugs had won approval this year so far, and Woodcock speculated that the agency would approve more than the 21 it approved last year.

May 6, 2011

Greenstone has introduced an authorized generic treatment for breast cancer, the generics subsidiary of Pfizer said.

PEAPACK, N.J. — Greenstone has introduced an authorized generic treatment for breast cancer, the generics subsidiary of Pfizer said.

The company announced the launch of exemestane tablets, an authorized generic version of Pfizer’s Aromasin. Aromasin is used to treat early breast cancer in menopausal women who already have taken the drug tamoxifen for two to three years, as well as breast cancer in women whose disease has worsened while taking tamoxifen, which is widely available as a generic.

May 5, 2011

A major depressive disorder treatment made by Pfizer significantly reduced the number and severity of moderate-to-severe hot flashes in postmenopausal women, compared with placebo, according to a new study.

WASHINGTON — A major depressive disorder treatment made by Pfizer significantly reduced the number and severity of moderate-to-severe hot flashes in postmenopausal women, compared with placebo, according to a new study.

May 4, 2011

Visine is looking to help consumers that experience eye irritation and redness during the summer months.

MORRIS PLAINS, N.J. — Visine is looking to help consumers that experience eye irritation and redness during the summer months.

Designed for use by those ages 6 years and older, new Visine Summer Spectrum Relief is designed to treat symptoms and protect eyes from further irritation by helping to supplement the natural tear film.

Visine Summer Spectrum Relief exclusively is available at CVS/pharmacy in the sun care aisle for $3.99 for a 0.5-fl.-oz. bottle.

May 3, 2011

Sales at generic drug maker Mylan increased by 12% during first quarter 2011, compared with first quarter 2010, the company said Tuesday.

PITTSBURGH — Sales at generic drug maker Mylan increased by 12% during first quarter 2011, compared with first quarter 2010, the company said Tuesday.

Sales for the three months ended March 31 were $1.45 billion, compared with $1.29 billion during the same period a year ago. Profits, meanwhile, were $104.2 million, compared with $61.1 million in first quarter 2010.

April 27, 2011

Pfizer on Wednesday launched its Gold range of child nutrition products, developed to meet the changing nutritional and feeding needs of young children. The Gold range of infant and follow-on formulas and growing-up milks provides the right balance of high-quality nutrients needed to support ideal health, growth and development in growing children.

MADISON, N.J. — Pfizer on Wednesday launched its Gold range of child nutrition products, developed to meet the changing nutritional and feeding needs of young children. The Gold range of infant and follow-on formulas and growing-up milks provides the right balance of high-quality nutrients needed to support ideal health, growth and development in growing children.

April 26, 2011

The American Pharmacists Association on Monday released its 2010 Pharmacy Today over-the-counter product survey and found that 92% of pharmacists walk a patient to the OTC section to assist with a product selection, noting that the average patient consult takes only three minutes of the patient's time.

WASHINGTON — The American Pharmacists Association on Monday released its 2010 Pharmacy Today over-the-counter product survey and found that 92% of pharmacists walk a patient to the OTC section to assist with a product selection, noting that the average patient consult takes only three minutes of the patient's time.

The survey also found that when a pharmacist makes an OTC brand recommendation, more than 8-in-10 consumers buy that product.

April 14, 2011

Drug manufacturers are coming up with new versions of their drugs for erectile dysfunction as those drugs’ loss of patent protection and subsequent generic competition draw near, according to published reports.

NEW YORK — Drug manufacturers are coming up with new versions of their drugs for erectile dysfunction as those drugs’ loss of patent protection and subsequent generic competition draw near, according to published reports.

April 13, 2011

A Food and Drug Administration expert panel has given a favorable vote to a drug made by Pfizer for tumors, Pfizer said Tuesday.

NEW YORK — A Food and Drug Administration expert panel has given a favorable vote to a drug made by Pfizer for tumors, Pfizer said Tuesday.

The FDA’s Oncologic Drugs Advisory Committee voted 8-2 that Sutent’s (sunitinib malate) benefits outweigh its risks in the treatment of unresectable pancreatic neuroendocrine tumors.

While the FDA is not bound by advisory committee votes, it takes them into consideration when deciding whether or not to approve a drug.

April 11, 2011

A drug originally developed by scientists in the Soviet Union to treat allergies and currently under investigation by Pfizer and Medivation did not yield significant results in a late-stage clinical trial of patients with Huntington disease, a disorder that leads to cognitive decline, the companies said Monday.

NEW YORK — A drug originally developed by scientists in the Soviet Union to treat allergies and currently under investigation by Pfizer and Medivation did not yield significant results in a late-stage clinical trial of patients with Huntington disease, a disorder that leads to cognitive decline, the companies said Monday.

April 7, 2011

The Food and Drug Administration has approved a drug made by GlaxoSmithKline and Xenoport for treating restless legs syndrome, the agency said Thursday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a drug made by GlaxoSmithKline and Xenoport for treating restless legs syndrome, the agency said Thursday.

The FDA approved Horizant (gabapentin enacarbil) as a once-daily treatment for moderate-to-severe RLS.

“People with restless legs syndrome can experience considerable distress from their symptoms,” FDA Division of Neurology Products director Russell Katz said. “Horizant provides significant help in treating these symptoms.”